Consensus Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Market Closed - OTC Markets Other stock markets 03:44:34 2024-05-17 pm EDT			5-day change	1st Jan Change
0.22 ^USD	0.00%		-49.66%	-67.02%

Apr. 16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Ayala Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0da42f3bd58eeef0555155b467bd1930.PzW1V0NNIBB8tEwNWgQo1w9wHb7OlYtxtL8pWaR6zFQ.C0H4LjA-cFgVwRVPMTN44mEdKP2NospI0e54DsMw-mFNdoASdxtWURLVeA~0b3cc97060425a7fe021c66528151354

Analyst Recommendations on Ayala Pharmaceuticals, Inc.

North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
North American Morning Briefing : Apple's China Conflict, Rate Hike Fears Continue to Weigh	23-09-08	DJ
ADVAXIS : Alliance Global Adjusts Advaxis' Price Target to $2.25 From $5, Maintains Buy Rating	21-04-19	MT
Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports	16-06-06	CI

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.22

Average target price

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ayala Pharmaceuticals, Inc.

Alliance Global Partners

Chiffre d''affaires - Rate of surprise

Company calendar